

Intranasal Fentanyl

Intranasal fentanyl is a fast, effective medicine for pain control. It is given by spraying the medicine into your nose. It is a great option when we do not yet have IV access.

We know the value of a pain plan for each person. We plan to transition you to the IV pain medicine (opioid) that works best when you have IV access. The key step in managing a pain crisis is to treat the pain early. This medicine helps us get a head start in treating your pain to avoid playing catch up. This has been shown to decrease the need for being admitted to the hospital.

Intranasal fentanyl is a very common medicine that we use to treat all kinds of pain, like, broken bones, burns, and other injuries. It is recommended as a national standard for rapid pain relief for a sickle cell pain crisis.

It is a fast-acting and easy-to-use medicine. We can dose it to each person's needs. It takes effect within a few minutes. Your child's age and weight are used to determine a safe and effective dose.

Like other opioid pain medications, fentanyl may cause side effects that are usually temporary and will go away. These include:

- drowsiness
- dizziness
- nausea

Intranasal fentanyl spray is not painful. Half of the dose will go into one nostril and the other half into the other nostril. All you need to do is stay still and breathe normally.

Our goal is to give the best care possible by helping you get control of your pain early.

References

- American College of Emergency Physicians (2023, June 22). *Managing sickle cell disease in the ED*. <https://www.acep.org/patient-care/sickle-cell/>
- Brandow, A.M., Carroll, C.P., Creary, S., Edwards-Elliott, R., Glassberg, J., Hurley, R.W., Kutlar, A., Seisa, M., Stinson, J., Strouse, J.J., Yusuf, F., Zempsky, W., & Lange, E. (2020). American Society of Hematology 2020 guidelines for sickle cell disease: Management of acute and chronic pain. *Blood Advances*, 4(12), 2656-2701. <https://doi.org/10.1182/bloodadvances.2020001851>
- Kavanaugh, P.L., Sprinz, P.G., Wolfgang, T.L., Killius, K., Champigny, M., Sobota, A., Dorfman, D., Barry, K., Miner, R., & Moses, J.M. (2015). Improving the management of vaso-occlusive episodes in the pediatric emergency department. *Pediatrics*, 136(4), e1016-e1025. <https://doi.org/10.1542/peds.2014-3470>
- Puri, L., Nottage, K.A., Hankins, J.S., & Anghelescu, D.L. (2018). State of the art management of acute vaso-occlusive pain in sickle cell disease. *Pediatric Drugs*, 20, 29-42. <https://doi.org/10.1007/s40272-017-0263-z>
- Rees, C.A., Brousseau, D.C., Ahmad, F.A., Bennett, J., Bhatt, S., Bogie, A., Brown, K.M., Casper, T.C., Chapman, L.L., Chumpitazi, C.E., Cohen, D.M., Dampier, C., Ellison, A.M., Grasemann, H., Hatabah, D., Hickey, R.W., Hsu, L.L., Bakshi, N., Leibovich, S., ... Morris, C.R. (2023). Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: A multicenter pediatric emergency medicine perspective. *American Journal of Hematology*, 98(4), 620-627. <https://doi.org/10.1002/ajh.26837>